VIRGINIA RETIREMENT SYSTEMS ET Al Purchases New Shares in Edwards Lifesciences Corporation $EW

Key Points

• Virginia Retirement Systems purchased 679,211 Edwards Lifesciences shares worth approximately $61.4 million, representing about 0.12% of the company. Institutional investors and hedge funds collectively own 79.46% of Edwards’ stock.
• Analyst sentiment remains favorable: 17 analysts rate the stock a Buy and six rate it a Hold, producing a consensus rating of “Moderate Buy” and an average price target of $100.27.
• Edwards exceeded quarterly expectations, reporting $0.78 in EPS versus the $0.74 consensus and $1.74 billion in revenue, up 13.6% year over year. The stock opened at $90.00, while company insiders have sold 5,045 shares worth approximately $457,749 over the past three months.

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 679,211 shares of the medical research company's stock, valued at approximately $61,441,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned approximately 0.12% of Edwards Lifesciences at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Rehmann Capital Advisory Group boosted its holdings in shares of Edwards Lifesciences by 2.1% in the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock worth $546,000 after buying an additional 130 shares during the period. Quadrant Capital Group LLC raised its holdings in shares of Edwards Lifesciences by 0.9% during the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company's stock valued at $1,288,000 after acquiring an additional 136 shares during the period. Stephens Inc. AR lifted its position in shares of Edwards Lifesciences by 5.4% in the 4th quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company's stock valued at $239,000 after acquiring an additional 144 shares in the last quarter. Aspen Investment Management Inc lifted its position in shares of Edwards Lifesciences by 1.5% in the 4th quarter. Aspen Investment Management Inc now owns 10,381 shares of the medical research company's stock valued at $885,000 after acquiring an additional 150 shares in the last quarter. Finally, Covestor Ltd boosted its stake in Edwards Lifesciences by 9.6% in the 4th quarter. Covestor Ltd now owns 1,784 shares of the medical research company's stock worth $152,000 after purchasing an additional 157 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Analyst Ratings Changes

Several equities analysts have weighed in on EW shares. UBS Group began coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 28th. They set a "buy" rating and a $110.00 price objective on the stock. Royal Bank Of Canada increased their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company an "outperform" rating in a report on Monday, July 13th. Truist Financial raised their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "hold" rating in a research report on Thursday, July 16th. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a report on Friday, July 24th. Finally, BTIG Research upped their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Tuesday, June 30th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $100.27.

Edwards Lifesciences Price Performance

NYSE EW opened at $90.00 on Monday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The stock's 50-day moving average is $89.73 and its two-hundred day moving average is $85.56. The firm has a market cap of $51.82 billion, a P/E ratio of 51.72, a price-to-earnings-growth ratio of 2.36 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm's revenue was up 13.6% compared to the same quarter last year. During the same period last year, the business earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the company's stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the sale, the vice president directly owned 17,984 shares in the company, valued at $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the firm's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 5,045 shares of company stock worth $457,749. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source